Pseudomonas aeruginosa: Mechanisms of Multidrug Resistance and Biofilm Formation

Introduction

Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen of significant concern in veterinary medicine, particularly in immunocompromised hosts, chronic wound infections, and respiratory disease in companion animals, livestock, and avian species. The organism is intrinsically resistant to a broad spectrum of antimicrobials and possesses a remarkable capacity to acquire additional resistance determinants through horizontal gene transfer and mutational adaptation. The convergence of multidrug resistance (MDR) and biofilm formation creates a therapeutic challenge that is distinct from planktonic susceptibility profiles. This reference article examines the molecular and biophysical mechanisms underlying MDR in P. aeruginosa, with emphasis on efflux pump systems, porin mutations, quorum sensing (QS) circuitry, and the structural biology of biofilm matrices.

Efflux Pump Systems and the Resistance-Nodulation-Division Superfamily

The primary mechanism of intrinsic and acquired multidrug resistance in P. aeruginosa is the overexpression of efflux pumps belonging to the resistance-nodulation-division (RND) superfamily. These tripartite complexes span the inner and outer membranes and function as proton motive force (PMF) driven transporters. The archetypal system is MexAB-OprM, which is constitutively expressed and confers resistance to beta-lactams, fluoroquinolones, tetracyclines, macrolides, and trimethoprim. The MexCD-OprJ, MexEF-OprN, and MexXY-OprM systems are regulated by local repressors and are inducible upon exposure to specific antimicrobials or mutational inactivation of their cognate regulatory genes [1, 2].

The PMF dependency of these pumps has been exploited in collateral sensitivity studies. Mahmud et al. demonstrated that PMF mismatch induced by gentamicin exposure can drive novobiocin sensitivity in P. aeruginosa, a phenomenon termed efflux mismatch. This occurs when the energetic demands of one pump system alter the membrane potential such that a second pump cannot function efficiently, leading to transient susceptibility [2]. This biophysical principle has implications for sequential antimicrobial therapy in veterinary settings.

The discovery of efflux pump inhibitors (EPIs) represents a promising adjunctive strategy. Rosado-Lugo et al. identified TXA11114, a small molecule EPI that potentiates levofloxacin activity against P. aeruginosa by disrupting the PMF gradient required for MexAB-OprM function [3]. EPIs do not directly kill the organism but restore the intracellular concentration of otherwise effluxed antimicrobials, thereby lowering the minimum inhibitory concentration (MIC) to clinically achievable levels.

Porin Mutations and Outer Membrane Permeability

The outer membrane of P. aeruginosa is characterized by low intrinsic permeability due to the predominance of narrow-channel porins, primarily OprF. Acquired resistance frequently involves the downregulation or loss of OprD, a specific porin that facilitates the entry of carbapenems such as imipenem and meropenem. Loss of OprD, often through mutational inactivation of the oprD gene or insertional elements, is a common mechanism of carbapenem resistance in clinical isolates [4, 5].

Alsharidi et al. demonstrated that imipenem-relebactam susceptibility in carbapenem-resistant P. aeruginosa is correlated with the presence of specific beta-lactamase classes and OprD status. Isolates with OprD loss combined with class A or D carbapenemases exhibited higher MICs to imipenem, and relebactam restored activity only when the resistance was mediated by class A beta-lactamases [5]. This underscores the necessity of genotypic characterization for accurate antimicrobial selection.

Aptamer-mediated outer membrane destabilization has been proposed as a strategy to overcome low permeability resistance. Selvam et al. showed that DNA aptamers targeting the lipopolysaccharide (LPS) core of P. aeruginosa disrupt outer membrane integrity, increasing the influx of otherwise excluded antimicrobials [6]. This approach is distinct from EPI strategies and targets the physical barrier of the cell envelope.

Beta-Lactamase Acquisition and Carbapenem Resistance

The acquisition of transferable beta-lactamase genes, particularly those encoding carbapenemases, has escalated the MDR phenotype in P. aeruginosa. The bla(AFM-1) gene, a novel class A carbapenemase, has been shown to undergo meropenem-driven amplification, leading to high-level cefiderocol resistance. Hong et al. demonstrated that exposure to meropenem selected for tandem repeat amplification of bla(AFM-1) in the chromosome, resulting in a 64-fold increase in cefiderocol MIC [7]. This mechanism of gene amplification is distinct from plasmid-mediated resistance and represents a stable, heritable adaptation.

The post-pandemic landscape has seen increased carbapenem resistance gene carriage. Abdelrahim et al. reported that clinical P. aeruginosa isolates from Egypt collected after the COVID-19 pandemic showed a higher prevalence of bla(NDM), bla(VIM), and bla(KPC) genes compared to pre-pandemic isolates, suggesting that antimicrobial pressure during the pandemic selected for resistant clones [4]. This trend is relevant to veterinary populations where similar selective pressures may occur.

Quorum Sensing and Virulence Network Integration

P. aeruginosa employs a hierarchical QS system comprising the Las, Rhl, and Pqs (MvfR) circuits. The Las system regulates the expression of extracellular virulence factors including elastase (LasB), exotoxin A, and alkaline protease. The Rhl system controls rhamnolipid production and swarming motility. The Pqs system, mediated by the MvfR (PqsR) regulator, directs the synthesis of 2-alkyl-4(1H)-quinolone (AQ) signals, including the Pseudomonas quinolone signal (PQS) and its precursor 4-hydroxy-2-heptylquinoline (HHQ) [1, 8].

The MvfR regulon is a critical target for QS inhibition. Ibisanmi et al. employed multimodal computational discovery to identify MvfR inhibitors that block the binding of the autoinducer to the transcriptional regulator, thereby suppressing downstream pyocyanin and lectin production [8]. These inhibitors, when combined with conventional antimicrobials, reduce the effective inoculum required for biofilm formation and increase the susceptibility of sessile cells to killing.

Sánchez-Mateos and Flores-Félix reviewed QS inhibition strategies including the use of natural products (e.g., baicalin, furanone derivatives), enzymatic degradation of signal molecules (e.g., lactonases, acylases), and monoclonal antibodies targeting QS signals [1]. The combination of QS inhibitors with antibiotics has been shown to synergistically reduce biofilm biomass and enhance antimicrobial penetration in vitro and in vivo [9].

Biofilm Structural Biology

The biofilm of P. aeruginosa is a structured community of cells embedded in a self-produced extracellular polymeric substance (EPS) composed of polysaccharides (alginate, Pel, Psl), extracellular DNA (eDNA), and proteins. The Pel polysaccharide is a cationic polymer that crosslinks with eDNA, providing structural integrity. The Psl polysaccharide mediates surface adhesion and cell-cell cohesion. Alginate, a linear copolymer of mannuronic and guluronic acids, is overproduced in mucoid variants associated with chronic infections [10, 11].

The transition from planktonic to biofilm growth is accompanied by metabolic reprogramming. Meng et al. demonstrated that baicalin, a flavonoid compound, in combination with cefotaxime, alters the metabolic flux of P. aeruginosa in biofilms, shifting from oxidative phosphorylation to fermentative pathways and reducing ATP availability for efflux pump activity [12]. This metabolic shift increases the susceptibility of biofilm-resident cells to antimicrobials that are otherwise ineffective against sessile populations.

The physical architecture of biofilms creates a diffusion barrier that limits antimicrobial penetration. Insero et al. showed that antimicrobial blue light (aBL) killing efficiency decreases as biofilm thickness increases, with a logarithmic relationship between optical density and bacterial survival. The EPS absorbs and scatters light, reducing the effective photon flux reaching deeper cell layers [11]. This biophysical constraint is relevant to photodynamic therapy approaches in veterinary wound management.

Dual-Targeting Biofilm Inhibitors

Chen et al. developed novel dual-targeting biofilm inhibitors that simultaneously disrupt the QS system and the EPS matrix. These compounds, based on a bis-indole scaffold, inhibit the PqsR regulator and chelate eDNA, thereby reducing both signal production and matrix stability [10]. The dual-targeting approach is advantageous because it reduces the likelihood of resistance emergence, as two independent pathways must be mutated for the organism to escape inhibition.

Antimicrobial Peptides and Membrane Disruption

Antimicrobial peptides (AMPs) represent a class of agents with activity against MDR P. aeruginosa. Khlaychinda et al. demonstrated that D-amino acid modification of an AMP enhances its proteolytic stability while maintaining its mechanism of membrane depolarization. The modified peptide, termed D-AMP, forms transient pores in the inner membrane, dissipating the PMF and causing rapid bactericidal action [13]. This mechanism is distinct from that of conventional antibiotics and is less susceptible to efflux pump-mediated resistance.

Zeng et al. characterized SMAP29, a sheep myeloid-derived AMP, which exhibits anti-inflammatory properties and rapid bactericidal activity against colistin-resistant P. aeruginosa. SMAP29 acts by disrupting the LPS bilayer and inducing membrane permeabilization within 5 minutes of exposure, a timescale that precludes adaptive resistance [14]. The anti-inflammatory component is beneficial in reducing host tissue damage during infection.

Phage Therapy and Bacteriophage-Mediated Control

Bacteriophage therapy has reemerged as an alternative strategy for MDR P. aeruginosa infections. Cunha et al. reviewed preclinical and clinical evidence for phage therapy, noting that lytic phages (e.g., members of the Myoviridae and Podoviridae families) can penetrate biofilms by expressing polysaccharide depolymerases that degrade the EPS [15]. Phage therapy is limited by the narrow host range of individual phages and the rapid emergence of phage-resistant mutants. However, the use of phage cocktails targeting multiple receptor binding proteins reduces the probability of resistance.

Genomic Epidemiology and High-Risk Lineages

Phylogenomic analyses have identified specific lineages of P. aeruginosa that are associated with outbreak potential and MDR dissemination. Chen et al. characterized the ST292 and ST235* sublineages in Taiwan, which carry multiple resistance determinants including bla(KPC), bla(VIM), and aac(6')-Ib. These lineages are characterized by a high degree of genomic plasticity, with frequent recombination events in the pilus and O-antigen biosynthesis loci [16]. The identification of high-risk lineages is critical for surveillance in veterinary populations, where clonal spread can occur through contaminated water sources or fomites.

Conclusion

The mechanisms of multidrug resistance in P. aeruginosa are multifactorial and interconnected. Efflux pump overexpression, porin loss, beta-lactamase acquisition, and biofilm formation collectively create a phenotype that is refractory to most conventional antimicrobials. The integration of QS inhibition, EPI therapy, and biofilm matrix disruption represents a rational approach to restoring susceptibility. Veterinary microbiologists must employ a combination of phenotypic susceptibility testing and genotypic characterization to guide therapy, as the resistance profile of a given isolate cannot be predicted from its species identification alone.

References

[1] Sánchez-Mateos J, Flores-Félix JD. Quorum sensing inhibition strategies for the control of Pseudomonas aeruginosa infections. World J Microbiol Biotechnol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42268336/

[2] Mahmud HA, Rahman MS, Ortiz E et al. Proton motive force mediated efflux mismatch drives gentamycin-novobiocin collateral sensitivity in Pseudomonas aeruginosa. bioRxiv. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42146568/

[3] Rosado-Lugo JD, Datta P, Altiti A et al. TXA11114: Discovery of an In Vivo Efficacious Efflux Pump Inhibitor (EPI) That Potentiates Levofloxacin Against Pseudomonas aeruginosa. Antibiotics (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42041309/

[4] Abdelrahim SS, Zaki S, Kotb DN. Increased Carbapenem resistance and gene carriage in Pseudomonas aeruginosa clinical isolates after the COVID-19 pandemic in Egypt. Mol Biol Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42234289/

[5] Alsharidi AI, Alhumaidi RA, Albarrag AM et al. In vitro activity of imipenem-relebactam against carbapenem-resistant Pseudomonas aeruginosa: correlation with carbapenem MICs and association with beta-lactamase classes. Front Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42182010/

[6] Selvam R, Yap MKK, Giacomazzi R et al. Aptamer-mediated outer membrane destabilization overcomes low permeability resistance in Pseudomonas aeruginosa. FEBS J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42053421/

[7] Hong H, Zhang T, Liu Y. Meropenem-driven amplification of bla(AFM-1) leads to high-level cefiderocol resistance in difficult-to-treat Pseudomonas aeruginosa. Drug Resist Updat. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42208082/

[8] Ibisanmi TA, Jiang X, Khan RA et al. Multimodal computational discovery of MvfR inhibitors targeting quorum sensing in multi-drug-resistant Pseudomonas aeruginosa. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42086791/

[9] Li H, Maiga A, Zhen H et al. Synergistic antimicrobial strategies: Quorum sensing inhibitors combined with conventional antibiotics for combating Pseudomonas aeruginosa infections. Biochem Biophys Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41966741/

[10] Chen W, Shang H, Zhang W et al. Novel dual-targeting biofilm inhibitors for potentiating antibiotic efficacy against multidrug-resistant Pseudomonas aeruginosa infections. J Adv Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42150716/

[11] Insero G, Maldonado-Carmona N, Panier T et al. Experiences and theory reveal a decrease in antimicrobial blue light killing efficiency as biofilm grows in a Pseudomonas aeruginosa model. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42106416/

[12] Meng X, Ning C, Lu X et al. The Effects of Baicalin in Combination with Cefotaxime on the Biofilm and Metabolic Reprogramming of Multidrug-Resistant Pseudomonas aeruginosa. Biomolecules. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42072719/

[13] Khlaychinda S, Suriya U, Roytrakul S et al. Enhanced proteolytic stability and distinct mechanisms of a D-amino acid-modified antimicrobial peptide against Pseudomonas aeruginosa. Sci Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42168333/

[14] Zeng Z, Wei M, Zhao D et al. SMAP29: an antibacterial peptide that possesses anti-inflammatory and fast bactericidal actions against colistin-resistant gram-negative bacteria. Microbiol Spectr. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42084406/

[15] Cunha GAD, Amaral RP, Dos Santos ALC et al. Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence. Microbiologyopen. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42071311/

[16] Chen CM, Tang HL, Ke SC et al. Emergence of outbreak-driving high-risk Pseudomonas aeruginosa lineages in Taiwan: phylogenomic insights into ST292 and the ST235* sublineage. Microb Genom. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42012470/

[17] Kong F, Zhang T, Liu Y et al. Photodynamic and antibiotic combination therapy against multidrug-resistant Pseudomonas aeruginosa wound infections in diabetic rats. Bioorg Chem. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42127741/

[18] Abdelmoneim HM, Alhudhaibi AM, Taha RH et al. Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa. Infection. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42113464/

[19] Sornsenee P, Pattaranggoon NC, Suksabay P et al. Probiotic Potential, Genomic Characterization, and In Silico Insights of Five Lactiplantibacillus plantarum Strains Isolated from Fermented Cacao Beans Against Multidrug-Resistant Pseudomonas aeruginosa. Antibiotics (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42041297/

[20] Zhao S, Tang J, Du Z et al. Generative active learning guided discovery of a tobramycin and ciprofloxacin adjuvant against multidrug-resistant Pseudomonas aeruginosa infections. Acta Pharm Sin B. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42039275/

[21] Sawant S, Shaikh S, Baldwin TC et al. Pseudomonas aeruginosa: associated pathogenesis, epidemiology, resistance mechanisms, host response and emerging treatment strategies. Arch Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42029769/